Jiménez-QuevedoPSerradorAPérez de PradoAPanM. Spanish Cardiac Catheterization and Coronary Intervention Registry. 25th Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2015). Rev Esp Cardiol (Engl Ed). 2016;69(12):1180–1189.
2.
SigwartUPuelJMirkovitchVJoffreFKappenbergerL. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316(12):701–706.
3.
SerruysPWde JaegerePKiemeneijF. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331(8):489–495.
4.
AlfonsoFByrneRARiveroFKastratiA. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63(24):2659–2673
5.
WindeckerSKolhPAlfonsoF. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–2619.
6.
HoffmannRMintzGS. Coronary in-stent restenosis—predictors, treatment and prevention. Eur Heart J. 2000;21(21):1739–1749.
7.
GoldbergSLLoussararianADe GregorioJDi MarioCAlbieroRColomboA. Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol. 2001;37(4):1019–1025.
8.
WestNERuygrokPNDiscoCM. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation. 2004;109(7):867–873.
9.
MehranRDangasGAbizaidAS. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872–1878.
10.
YilmazSAkbogaMKArasDTopalogluS. Evaluation of the predictive value of CHA2DS2-VASc score for in-stent restenosis. Angiology. 2018;69:38–42. doi:10.1177/0003319717700746
11.
GageBFWatermanADShannonW. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870.
12.
MorillasPPallarésVFácilaL. The CHADS2 score to predict stroke risk in the absence of atrial fibrillation in hypertensive patients aged 65 years or older. Rev Esp Cardiol (Engl Ed). 2015;68(6):485–491.
13.
LiuFDShenXLZhaoR. Predictive role of CHADS2 and CHA2DS2-VASc scores on stroke and thromboembolism in patients without atrial fibrillation: a meta-analysis. Ann Med. 2016;48(5):367–375.
14.
PegueroJGIssaOPodestaCElmahdyHMSantanaOLamasGA. Usefulness of the CHA2DS2VASc score to predict postoperative stroke in patients having cardiac surgery independent of atrial fibrillation. Am J Cardiol. 2015;115(6):758–762.
15.
StöllbergerCWegnerCFinstererJ. CHADS2- and CHA2DS2VASc scores and embolic risk in left ventricular hypertrabeculation /noncompaction. J Stroke Cerebrovasc Dis. 2013;22(6):709–712.
16.
ChaMJLeeHSKimYDNamHSHeoJH. The association between asymptomatic coronary artery disease and CHADS2 and CHA2DS2VASc scores in patients with stroke. Eur J Neurol. 2013;20(9):1256–1263.
17.
CetinMCakiciMZencirC. Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. Am J Cardiol. 2014;113(6):950–956.
18.
PuurunenMKKiviniemiTSchlittA. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Thromb Res. 2014;133(4):560–566.
19.
HuangSSChenYHChanWLHuangPHChenJWLinSJ. Usefulness of the CHADS2 score for prognostic stratification of patients with acute myocardial infarction. Am J Cardiol. 2014;114(9):1309–1314.
20.
LuDYHuangCCHuangPH. Usefulness of the CHADS(2) Score for prognostic stratification in patients with coronary artery disease having coronary artery bypass grafting. Am J Cardiol. 2017;119(6):839–844.
21.
KirigayaHKatoSGyotokuD. Higher CHADS2 score is associated with impaired coronary flow reserve: a study using phase contrast cine magnetic resonance imaging. Int J Cardiol. 2016;221:800–805.
22.
HsuPCChiuCAChuCY. CHADS2 score and risk of new-onset peripheral arterial occlusive disease in patients without atrial fibrillation: a nationwide cohort study in Taiwan. J Atheroscler Thromb. 2015;22(5):490–498.
23.
SalibaWGronichNBarnett-GrinessORennertG. Usefulness of CHADS2 and CHA2DS2-VASc Scores in the prediction of new-onset atrial fibrillation: a population-based study. Am J Med. 2016;129(8):843–849.
24.
NaccarelliGVPanaccioMPCumminsGTuN. CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients. Am J Cardiol. 2012;109(10):1526–1533.
25.
PoliDAntonucciEPengoVTestaSPalaretiG. Comparison of HAS-BLED and HAS-BED versus CHADS(2) and CHA(2)DS(2)VASC stroke and bleeding scores in patients with atrial fibrillation. Am J Cardiol. 2017;119(7):1012–1016.
26.
YoshihisaAWatanabeSKannoY. The CHA(2)DS(2)-VASc score as a predictor of high mortality in hospitalized heart failure patients. ESC Heart Fail. 2016;3(4):261–269.
27.
HamidTChoudhuryTRAndersonSG. Does the CHA2DS2-Vasc score predict procedural and short-term outcomes in patients undergoing transcatheter aortic valve implantation?Open Heart. 2015;2(1):e000170.
28.
WellesCCWhooleyMANaBGanzPSchillerNBTurakhiaMP. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2011;162(3):555–561.
29.
ChouRHHuangPHHsuCYLeuHBHuangSSHuangCC. CHADS2 score predicts risk of contrast-induced nephropathy in stable coronary artery disease patients undergoing percutaneous coronary interventions. J Formos Med Assoc. 2016;115(7):501–509.
